Originally published by our sister publication Infectious Disease Special Edition
By Ethan Covey
Treating patients with chronic hepatitis C virus (HCV) with direct-acting antivirals (DAAs) is associated with improved liver and non-liver outcomes, as well as overall survival rates, according to data from a large retrospective cohort study.
The study included data from 245,596 patients with HCV from 2010 through 2021, drawn from a database of about 60 million people with private insurance in the